HCmed Innovations

What HCmed Innovations does

HCmed Innovations Co., Ltd. is a Taipei-based CDMO specializing in vibrating mesh nebulizer platforms for drug-device combination products. Founded in 2014 and listed on the Taiwan Emerging Stock Market (TPEX: 6934), the company develops customizable nebulizers that pair with partner pharmaceutical formulations, including solutions, suspensions, biologics, high-viscosity drugs, and liposomes. Core products are Pulmogine, a continuous-mode mesh nebulizer FDA-cleared and approved for use with Pulmozyme in cystic fibrosis, and AdheResp, an adaptive breath-actuated mesh nebulizer with embedded Bluetooth connectivity for adherence and treatment monitoring. Engineering and manufacturing footprint spans a GMP facility in New Taipei City, an R&D and production site in Wuxi (Wuxi International Life Science Innovation Park, supported by AstraZeneca China), and a UK subsidiary (HCMED UK LIMITED, Chichester) for European customization.

HCmed generates revenue through a multi-pronged B2B CDMO model: hardware sales of proprietary mesh nebulizer devices, contract development and manufacturing services with upfront and milestone payments under global development agreements, royalties on partner net sales post-commercialization, and long-term commercial supply agreements. Named development partners include CSL Behring (plasma-derived immunoglobulin CSL787, Phase I initiated December 2020), United Therapeutics (PAH programs), AeroRx Therapeutics (nebulized LABA/LAMA for COPD), and Cellics Therapeutics (Cellular Nanosponge). Regulatory clearances span FDA 510(k) for both flagship devices, TFDA, NMPA, and inclusion in the Australian Register of Therapeutic Goods; HCmed also operates analytical services including APSD characterization for combination product development.

The company's go-to-market is enterprise field sales into global pharmaceutical and biotech programs, supplemented by active participation in respiratory and drug delivery conferences (ERS, DDL, ATS, RDD, CPHI, MVIC, NACFC), scientific publications (ONdrugDelivery and similar trade journals), and joint webinars with analytical partners. Distribution combines direct sales to Taiwanese hospitals, exclusive distribution of Pulmogine in China via SinoMedCare BioTech, and customized OEM/white-label device supply to global pharma partners. Recent strategic priorities include scaling commercial supply through a newly opened manufacturing facility with doubled capacity, advancing the AdheResp commercial launch following its 2025 FDA clearance, and executing a global nebulizer collaboration with Aerogen announced in July 2025.

Name

HCmed Innovations

Legal name

HCmed Innovations Co., Ltd.

Website

https://hcmed-inno.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

HCmed Innovations is a Taiwan-listed CDMO (TPEX: 6934) that develops customizable vibrating mesh nebulizers for pharmaceutical drug-device combination products, serving global biotech and pharma partners with breath-actuated devices, connectivity, and end-to-end combination product development services.

Ownership category

akta.pro rank

Product category

Inhalation Drug Delivery Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

akta.pro secondary industries

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Inhalation drug delivery
• Mesh nebulizer technology
• Drug-device combination
• Respiratory CDMO
• Breath-actuated nebulizers

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Device Sales: Sale of vibrating mesh nebulizer devices including Pulmogine, AdheResp, and Deepro. Devices are sold directly to pharmaceutical partners and through distribution networks.
2. CDMO Development Services: Contract development and manufacturing organization services providing comprehensive platform from concept to commercialization for drug-nebulizer combination products. Revenue recognized through development milestones.
3. Development Milestones: Upfront payments and device development milestones received from pharmaceutical partners under global development agreements. Revenue recognized per contractual milestones.
4. Royalties: Royalties from global net sales of pharmaceutical formulations for use with combination products upon commercialization.
5. Commercial Supply: Long-term commercial supply agreements for customized nebulizing devices to pharmaceutical partners post-regulatory approval.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

HCmed Innovations is a CDMO specializing in vibrating mesh nebulizer platforms for drug-device combination products, offering customizable hardware (Pulmogine continuous-mode and AdheResp breath-actuated nebulizers with embedded Bluetooth connectivity) and end-to-end services from concept to commercialization including device customization, clinical supply support, regulatory guidance, scale-up, and APSD analytical services for solutions, suspensions, biologics, and liposome formulations.

Product overview

HCmed Innovations is a CDMO (Contract Development and Manufacturing Organization) specializing in drug-nebulizer combination products, offering customizable vibrating mesh nebulizer platforms. The core product portfolio includes Pulmogine (continuous mode nebulizer) and AdheResp (breath-actuated nebulizer with connectivity), supported by mobile application for treatment monitoring. Services encompass breath actuation technology, connectivity integration, customization and development, clinical supply support, regulatory guidance, and commercialization assistance. The company also provides APSD analytical services for aerodynamic particle size distribution testing.

Differentiator

Problem solved

Functional benefit

Brands

• Pulmogine: Continuous mode vibrating mesh nebulizer brand for delivering inhaled medications directly into airways.
• AdheResp
• Deepro

Products and services

• Pulmogine Continuous mode vibrating mesh nebulizer designed for efficient delivery of inhaled medications for respiratory diseases. Capable of nebulizing solutions, suspensions, biologics, and high viscosity drugs; FDA 510(k) cleared, NMPA approved, included in Australian Register of Therapeutic Goods, and FDA approved for use with Pulmozyme for cystic fibrosis patients.
• AdheResp Breath-actuated mesh nebulizer with adaptive breath-actuation technology that generates aerosol exclusively during inhalation, featuring built-in Bluetooth connectivity for treatment monitoring and adherence tracking. World's first adaptive breath-actuated mesh nebulizer with embedded connectivity, FDA 510(k) cleared, and TFDA cleared.
• Deepro Vibrating mesh nebulizer with IP55 water resistance rating, marketed in Europe (Germany, France, Italy, Spain) and Brazil. A legacy first-generation product in HCmed's portfolio.
• Drug-Device Combination CDMO Services Contract development and manufacturing services covering breath actuation, connectivity, customization and development, clinical supply support, regulatory support and scale-up, and commercialization for pharmaceutical and biotech partners developing drug-nebulizer combination products.
• APSD Analytical Services

Quantifiable outcome

• Delivery efficiency reaching 88% with breath-actuated nebulizer vs 40% with continuous output devices
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

13 partnerships are on record, tiered core and minor.

• CSL BehringcoreStrategic or Co-development Partner · 4 May 2021Global development agreement for plasma-derived immunoglobulin (CSL787) delivered via HCmed's vibrating-mesh nebulizing device. CSL Behring has sole responsibility for development and commercialization; HCmed leads device customization. Phase I trial initiated December 2020. HCmed receives upfront payment, development milestones, and royalties on global net sales.
• United TherapeuticscoreStrategic or Co-development PartnerCollaboration to develop pulmonary arterial hypertension (PAH) treatment products combining HCmed's nebulizer technology with United Therapeutics' expertise in rare pulmonary diseases. First development milestone achieved, generating milestone revenue for HCmed.
• AeroRx TherapeuticscoreStrategic or Co-development PartnerDevelopment of nebulized LABA/LAMA combination solution for COPD treatment using breath-actuated nebulizer. Both parties have confirmed future collaboration framework and content.
• Cellics TherapeuticsminorStrategic or Co-development PartnerCollaboration to develop nebulized Cellular Nanosponge combination product for treatment of bacterial infections and inflammatory diseases.
• Formosa Laboratories (台耀化學)coreStrategic or Co-development PartnerStrategic alliance with Formosa Laboratories and Formosa Pharmaceuticals to expand inhalation treatment CDMO business. Combines HCmed's nebulizers, Formosa Laboratories' drug development services, and Formosa Pharma's APNT nano technology platform to provide one-stop CDMO services for international pharmaceutical customers.
• Formosa Pharmaceuticals (台新藥)coreStrategic or Co-development PartnerStrategic alliance forming global CDMO for inhalation treatment drugs using APNT nano technology platform combined with HCmed's nebulizer technology.
• SinoMedCare BioTech Co., Ltd. (SMC)coreChannel Partner/ Reseller/ DistributorExclusive distributor of Pulmogine vibrating mesh nebulizer in China.
• AstraZeneca China / Wuxi International Life Science Innovation ParkminorStrategic or Co-development PartnerSelected as first batch company to join Wuxi International Life Science Innovation Park anchored by AstraZeneca China. Building R&D center and production facility in the park.
• AerogencoreStrategic or Co-development PartnerGlobal strategic collaboration for nebulization therapy announced July 2025.
• EbenbuildminorStrategic or Co-development PartnerJoint research on adaptive breath-actuated mesh nebulizers using in silico evidence to demonstrate lung deposition optimization (2024 DDL Conference poster).
• NanoformminorStrategic or Co-development PartnerJoint research on increasing lung dose of inhaled suspensions using nanosuspension formulations delivered by breath-actuated mesh nebulizer (2024 DDL Conference poster).
• University of HertfordshireminorStrategic or Co-development PartnerCollaborative research on enhanced APSD testing method for AdheResp Smart Breath-actuated Mesh Nebulizer presented at 2025 RDD Conference.
• Intertek MelbournminorStrategic or Co-development PartnerJoint webinar on drug-nebulizer combination product development covering formulation and device considerations, and analytical testing methods.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Aerogen: Aerogen is the global leader in vibrating mesh nebulizer technology for acute care and inhalation drug delivery. Directly comparable as the primary competitor in mesh nebulizer space and now also HCmed's strategic partner; both companies target the same pharma customers for drug-device combination products.
• PARI Pharma: PARI Pharma is the CDMO arm of PARI Medical Holding, specializing in mesh nebulizer-based drug-device combination products (eFlow technology). Highly comparable business model offering customizable nebulizer platforms and CDMO services to pharmaceutical partners developing inhaled therapies.
• Vectura Fertin Pharma: Vectura Fertin Pharma (formerly Vectura, spun out of Philip Morris) is a specialist inhaled drug delivery company offering formulation, device, and development services for inhaled therapeutics. Comparable as an inhalation-focused CDMO serving pharmaceutical partners across the drug-device combination value chain.

Broad incumbents

• Aptar Pharma: Aptar Pharma is a large drug delivery device manufacturer offering inhalation, injectable, and nasal spray platforms including mesh-based nebulizers. Comparable as an established provider of device platforms and CDMO services for inhaled pharmaceutical products, though broader in scope than HCmed's nebulizer-only focus.
• Hovione: Hovione is a global pharmaceutical CDMO with established inhalation drug development and manufacturing capabilities including particle engineering and formulation services. Comparable as a pharma CDMO serving inhaled drug development needs, though broader in scope with API and oral dose capabilities.
• Catalent: Catalent is a major global pharmaceutical CDMO with inhalation and soft mist inhaler development capabilities. Comparable as a large-scale pharma services provider for inhaled drug-device combination products, though serving a much broader range of dosage forms and therapeutic areas.
• Omron Healthcare: Omron Healthcare is a large medical device manufacturer with a significant nebulizer product portfolio including compressor and mesh nebulizers for consumer and clinical markets. Comparable as a manufacturer of nebulization devices, though focused on direct sales rather than CDMO partnerships.
• Philips Respironics: Philips Respironics is a major respiratory care device manufacturer offering nebulizers, ventilators, and sleep therapy equipment. Comparable as a large established player in respiratory drug delivery devices, though operates in broader respiratory care rather than focusing on pharma CDMO partnerships.
• Drive DeVilbiss Healthcare: Drive DeVilbiss Healthcare is a medical device manufacturer with a long-standing nebulizer product line including compressor and ultrasonic nebulizers. Comparable as a manufacturer of nebulization devices for respiratory therapy, though primarily focused on direct medical equipment sales rather than pharma CDMO.

Emerging players

• Insmed: Insmed is a biopharmaceutical company that developed ARIKAYCE (amikacin liposome inhalation suspension) delivered via nebulizer for nontuberculous mycobacterial lung disease. Comparable as a user of inhaled drug delivery technology via partnership with nebulizer manufacturers, representing the type of pharma customer HCmed serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hcmed-innovations-co.-ltd./mycompany/?viewAsMember=true

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HCmed Innovations